Alere Inc (ALR) announced its most recent quarterly financial results on Tuesday, Sep-6-2016. ALR reported $-0.46 earnings per share for the quarter, missing the analyst consensus estimate by $-1.04. Analysts had a consensus of $0.58. The company posted revenue of $611.10 million in the period, compared to analysts expectations of $607.44 million. ALR’s revenue was down -2.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Alere Inc closed down -0.69 points or -1.76% at $38.44 with 7,76,270 shares getting traded on Thursday. Post opening the session at $38.7, the shares hit an intraday low of $38.31 and an intraday high of $39.12 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Apr 27, 2016, Carla Flakne (VP, Chief Accounting Officer) sold 10,000 shares at $42.44 per share price. According to the SEC, on Apr 12, 2016, Carol R Goldberg (director) sold 110 shares at $39.46 per share price. On Feb 3, 2016, Melissa Guerdan (SVP, Global Quality & Reg.) sold 2,500 shares at $54.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics patient self-testing consumer diagnostics and corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time deliver care and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD) its 50/50 joint venture with The Procter & Gamble Company (P&G).